196 related articles for article (PubMed ID: 25010905)
1. Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing.
Pavía-Jiménez A; Tcheuyap VT; Brugarolas J
Nat Protoc; 2014 Aug; 9(8):1848-59. PubMed ID: 25010905
[TBL] [Abstract][Full Text] [Related]
2. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples.
Dong Y; Manley BJ; Becerra MF; Redzematovic A; Casuscelli J; Tennenbaum DM; Reznik E; Han S; Benfante N; Chen YB; Arcila ME; Aras O; Voss MH; Feldman DR; Motzer RJ; Fabbri N; Healey JH; Boland PJ; Chawla M; Durack JC; Lee CH; Coleman JA; Russo P; Hakimi AA; Cheng EH; Hsieh JJ
Eur Urol Focus; 2017 Dec; 3(6):590-598. PubMed ID: 28753786
[TBL] [Abstract][Full Text] [Related]
3. Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.
Thong AE; Zhao H; Ingels A; Valta MP; Nolley R; Santos J; Young SR; Peehl DM
Urol Oncol; 2014 Jan; 32(1):43.e23-30. PubMed ID: 23911681
[TBL] [Abstract][Full Text] [Related]
4. Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients.
Grisanzio C; Seeley A; Chang M; Collins M; Di Napoli A; Cheng SC; Percy A; Beroukhim R; Signoretti S
J Pathol; 2011 Oct; 225(2):212-21. PubMed ID: 21710693
[TBL] [Abstract][Full Text] [Related]
5. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma.
Sivanand S; Peña-Llopis S; Zhao H; Kucejova B; Spence P; Pavia-Jimenez A; Yamasaki T; McBride DJ; Gillen J; Wolff NC; Morlock L; Lotan Y; Raj GV; Sagalowsky A; Margulis V; Cadeddu JA; Ross MT; Bentley DR; Kabbani W; Xie XJ; Kapur P; Williams NS; Brugarolas J
Sci Transl Med; 2012 Jun; 4(137):137ra75. PubMed ID: 22674553
[TBL] [Abstract][Full Text] [Related]
6. A renal cell carcinoma tumorgraft platform to advance precision medicine.
Elias R; Tcheuyap VT; Kaushik AK; Singla N; Gao M; Reig Torras O; Christie A; Mulgaonkar A; Woolford L; Stevens C; Kettimuthu KP; Pavia-Jimenez A; Boroughs LK; Joyce A; Dakanali M; Notgrass H; Margulis V; Cadeddu JA; Pedrosa I; Williams NS; Sun X; DeBerardinis RJ; Öz OK; Zhong H; Seshagiri S; Modrusan Z; Cantarel BL; Kapur P; Brugarolas J
Cell Rep; 2021 Nov; 37(8):110055. PubMed ID: 34818533
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation.
Yun EJ; Lin CJ; Dang A; Hernandez E; Guo J; Chen WM; Allison J; Kim N; Kapur P; Brugarolas J; Wu K; He D; Lai CH; Lin H; Saha D; Baek ST; Chen BPC; Hsieh JT
Clin Cancer Res; 2019 Jul; 25(14):4542-4551. PubMed ID: 31000589
[TBL] [Abstract][Full Text] [Related]
8. BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation.
Wang L; Park P; La Marca F; Than KD; Lin CY
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1013-24. PubMed ID: 25431339
[TBL] [Abstract][Full Text] [Related]
9. PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.
Huang B; Fu SJ; Fan WZ; Wang ZH; Chen ZB; Guo SJ; Chen JX; Qiu SP
Cancer Lett; 2016 Jun; 376(1):148-54. PubMed ID: 27037060
[TBL] [Abstract][Full Text] [Related]
10. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
[TBL] [Abstract][Full Text] [Related]
11. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.
Gassenmaier M; Chen D; Buchner A; Henkel L; Schiemann M; Mack B; Schendel DJ; Zimmermann W; Pohla H
Stem Cells; 2013 Aug; 31(8):1467-76. PubMed ID: 23630186
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors.
Cho YB; Hong HK; Choi YL; Oh E; Joo KM; Jin J; Nam DH; Ko YH; Lee WY
J Surg Res; 2014 Apr; 187(2):502-9. PubMed ID: 24332554
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of renal cancer stem cells from patient-derived xenografts.
Hasmim M; Bruno S; Azzi S; Gallerne C; Michel JG; Chiabotto G; Lecoz V; Romei C; Spaggiari GM; Pezzolo A; Pistoia V; Angevin E; Gad S; Ferlicot S; Messai Y; Kieda C; Clay D; Sabatini F; Escudier B; Camussi G; Eid P; Azzarone B; Chouaib S
Oncotarget; 2016 Mar; 7(13):15507-24. PubMed ID: 26551931
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
Yuen JS; Sim MY; Siml HG; Chong TW; Lau WK; Cheng CW; Huynh H
Br J Cancer; 2011 Mar; 104(6):941-7. PubMed ID: 21407223
[TBL] [Abstract][Full Text] [Related]
15. Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.
Colombo PE; du Manoir S; Orsett B; Bras-Gonçalves R; Lambros MB; MacKay A; Nguyen TT; Boissière F; Pourquier D; Bibeau F; Reis-Filho JS; Theillet C
Oncotarget; 2015 Sep; 6(29):28327-40. PubMed ID: 26334103
[TBL] [Abstract][Full Text] [Related]
16. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 detection using
Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
19. A novel murine model of human renal cell carcinoma spinal metastasis.
Wang L; Rahman S; Lin CY; Valdivia J; Than K; La Marca F; Park P
J Clin Neurosci; 2012 Jun; 19(6):881-3. PubMed ID: 22516545
[TBL] [Abstract][Full Text] [Related]
20. High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma.
Wolff NC; Pavía-Jiménez A; Tcheuyap VT; Alexander S; Vishwanath M; Christie A; Xie XJ; Williams NS; Kapur P; Posner B; McKay RM; Brugarolas J
Oncotarget; 2015 Jul; 6(19):16951-62. PubMed ID: 26219258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
